We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

kindr currently serves patients in the United States only. Content is for informational purposes elsewhere.

Non-hormonal \u00b7 Vasomotor

Fezolinetant (Veozah): non-hormonal hot flash option

Fezolinetant is an NK3 receptor antagonist that blocks the KNDy neuron pathway driving hot flashes. Effective non-hormonal option for women who can't or won't use estrogen. Requires LFT monitoring.

Key points

  • Baseline LFTs
  • Repeat monthly x3 then periodically
  • Not for hepatic impairment

Frequently asked questions

How effective is fezolinetant?

~60% reduction in moderate-to-severe hot flashes at 12 weeks.

What's the monitoring?

LFTs at baseline, month 1, 2, 3, then periodically.

Cost?

Roughly $550/month without insurance.

Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.

Request your Longevity Consult →

Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service

Medically reviewed by Kindr Health Clinical Team · Last reviewed 2026-06-19. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.

Ask Dot